-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is characterized by brain damage and neuronal loss, leading to occasional memory loss and other cognitive impairments, including attention, attention, visuospatial ability, mental processing speed, executive function, and speech fluency And deficiencies in speech and language skills
.
With the development of AD, the deterioration of these cognitive symptoms will accelerate in severity and frequency, which may lead to social rejection of patients, caregivers, and family members, and a decline in the quality of life
.
The currently approved treatments for AD are symptomatic and aim to temporarily slow down the development of symptoms by modulating neurotransmission-NMDA receptor antagonists
The currently approved treatments for AD are symptomatic and aim to temporarily slow down the development of symptoms by modulating neurotransmission-NMDA receptor antagonists
Recently, experts from the Spanish Memory Clinic conducted a research report on the neuropsychology, neuropsychology and life of patients with mild to moderate Alzheimer’s disease (AD) on plasma exchange (PE) and albumin exchange.
This is a Phase 2b/3 trial (Alzheimer’s Disease Albumin Replacement Management [AMBAR] study)
.
The results were published in the journal Alzheimer Dementia
manage
347 patients were randomized to placebo (sham PE) and PE three treatment groups with the low / high dose of albumin, while / do not use intravenous immune globulin (of IVIG)
.
Specific test measurements were taken at baseline, month 2 (regular PE once a week), months 6, 9 and 12 (low volume PE [LVPE] once a month), and month 1
immunity
The results showed that at the 14th month, the language fluency and processing speed of PE-treated mild AD patients were improved compared with placebo (the effect size: >100%; P value: 0.
03-0.
001)
.
The moderate AD cohort significantly improved short-term verbal memory (effect size: 94%->100%; P value: 0.
The results showed that at the 14th month, the language fluency and processing speed of PE-treated mild AD patients were improved compared with placebo (the effect size: >100%; P value: 0.
Changes in Rey Auditory and Speech Learning Test Scores in AD Patients
In summary, AD patients treated with PE have improved memory, language ability, processing speed and QoL-AD
.
However, no deterioration in their psychological and emotional state was observed
In summary, AD patients treated with PE have improved memory, language ability, processing speed and QoL-AD
references:
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
Leave a message here
